Top FDA Official Blames Federal Drug Scheduling System for Inhibiting CBD Research
Lowell Schiller, the FDA Principal Associate Commissioner for Policy, has said that the drug scheduling system of the FDA has hampered the ability of the scientific community to research CBD, and the FDA is now scrambling to fill the knowledge gaps that would have been filled long ago. Schiller made these remarks while speaking at the 2019 Hemp Business Summit organized by the National Industrial Hemp Council on Tuesday. The FDA official kept repeating that the agency was “excited” about the potential of CBD. During his speech, Schiller emphasized that the FDA has regulatory authority over hemp and any products…






